Loss of circulating CD27+ memory B cells and CCR4+ T cells occurring in association with elevated EBV loads in XLP patients surviving primary EBV infection

Blood

Volumn 103, Issue 5, 2004, Pages 1625-1631

  Malbran, Alejandro ^b   Belmonte, Liliana ^b   Ruibal Ares, Beatriz ^b   Baré, Patricia ^b   Massud, Ivana ^b   Parodi, Cecilia ^b   Felippo, Marta ^b   Hodinka, Richard ^b   Haines, Kathleen ^b   Nichols, Kim E ^b   De Bracco, María M ^a  

^a INST DE INVEST HEMATOLOGICAS   (Argentina)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD27 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CXCR3; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; HUMAN; HYPOGAMMAGLOBULINEMIA; LONGITUDINAL STUDY; LYMPHOCYTE COUNT; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MEMORY CELL; MONONUCLEOSIS; PRIORITY JOURNAL; T LYMPHOCYTE; TH1 CELL; TH2 CELL; VIRUS INFECTION; VIRUS LOAD; X CHROMOSOME LINKED DISORDER; X CHROMOSOME LINKED LYMPHOPROLIFERATIVE DISEASE;

EID: 10744226908     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-07-2525     Document Type: Article

References (29)

1. Purtilo DT, Cassel CK, Yung JPS, et al. X-linked recessive progressive combined variable immunodeficiency (Duncan's disease). Lancet. 1975;1:935-941.
2. Morra M, Howie D, Grande MS, et al. X-linked lymphoproliferative disease: a progressive immunodeficiency. Annu Rev Immunol. 2001;19:657-682.
3. Seemayer TA, Gross TG, Maarten-Egeler R, et al J. X-linked lymphoproliferative disease: twenty-five years after discovery. Pediatr Res. 1995;38:471-478.
4. Malbran A, Belmonte L, Ruibal-Ares B, Bare P, de Bracco MME. X-linked lymphoproliferative syndrome, EBV infection and impaired regulation of cell-mediated cytotoxicity. Medicina (Buenos Aires). 2003;63:70-76.
5. Sayos J, Wu C, Morra M, et al. The X-linked lymphoproliferative-disease gene product SAP regulates signals through the co-receptor SLAM. Nature. 1998;395:462-469.
6. Coffey AJ, Brooksbank RA, Brandau O, et al. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in the SH2 domain encoding gene. Nat Genet. 1998;20:120-135.
7. Nichols KE, Harkin DP, Levitz S, et al. Inactivating mutations in a SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc Natl Acad Sci U S A. 1998;95:13765-13770.
8. Sumegi J, Huang D, Lanyi A, et al. Correlation of mutations of the SH2D1A gene and Epstein-Barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease. Blood. 2000;96:3118-3125.
9. Sullivan JL, Byron KS, Brewster FE, Purtilo DT. Deficient natural killer cell activity in X-linked lymphoproliferative syndrome. Science. 1980;210:543-545.
10. Seeley J, Sakamoto K, Ip SH, Hansen PW, Purtilo DT. Abnormal lymphocyte subsets in X-linked lymphoproliferative syndrome. J Immunol. 1981;127:2618-2627.
11. Czar MJ, Kersh EN, Mijares LA, et al. Altered lymphocyte responses and cytokine production in mice deficient in the X-linked lymphoproliferative disease gene SH2D1A/DSHP/SAP. Proc Natl Acad Sci U S A. 2001;98:7449-7454.
12. Arico M, Imashuku S, Clementi R, et al. Hemophagocytic lymphohistiocytosis due to germline mutations in SH2D1A, the X-linked lymphoproliferative disease gene. Blood. 2001;97:1131-1133.
13. Gilmour K, Gaspar HB, Cranston T, et al. Diagnosis of X-linked lymphoproliferative disease by the analysis of SAP expression. Eur J Immunol. 2000;30:1691-1697.
14. Check IJ, Piper M. Quantification of immunoglobulins. In: Balows A, Hauser WJ, Hernmann KL, Isenberg HD, Shadany HJ, eds. Manual of Clinical Immunology. 3rd ed. Washington DC: American Society of Microbiology; 1986;38:712-715.
15. Niesters HGM, van Esser J, Fries E, Wolthers KC, Cornelissen J, Osterhaus ADME. Development of a real-time quantitative assay for detection of Epstein-Barr virus. J Clin Microbiol. 2000;38:712-715.
16. McLaughlin P, Grillo-López A, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsing indolent lymphoma: half of patients respond to a four dose treatment program. J Clin Oncol. 1998;16:2825-2833.
17. Klein U, Rajewsky K, Kuppers R. Human immunoglobulin (Ig) M+ IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J Exp Med. 1998;188:1679-1689.
18. Kim CH, Rott L, Kunkel EJ, et al. Rules of chemokine receptor association with T-cell polarization in vivo. J Clin Invest. 2001;108:1331-1339.
19. Okano M, Bashir RM, Davis JR, Purtilo DT. Detection of primary Epstein-Barr virus infection in a patient with X-linked lymphoproliferative disease receiving immunoglobulin prophylaxis. Am J Hematol. 1991;36:294-296.
20. Van der Kolk LE, Baars JW, Prins MH, van Oers MHJ. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood. 2002;100:2257-2259.
21. + IgM-IgD) in subgroups of patients with common variable immunodeficiency: a new approach to classify a heterogeneous disease. Blood. 2002;99:1544-1551.
22. Grierson H, Purtilo DT. Epstein-Barr virus infection in males with the X-linked lymphoproliferative syndrome. Ann Int Med. 1987;106:538-545.
23. Crotty S, Kersh EN, Cannons J, Schwartzberg PL, Ahmed R. SAP is required for generating long-term humoral immunity. Nature. 2003;421:282-287.
24. Howie D, Okamoto S, Rietdjik S, et al. The role of SAP in murine CD150 (SLAM)-mediated T-cell proliferation and interferon γ production. Blood. 2002;100:2899-2907.
25. Okano M, Thiele GM, Purtilo DT. Variable presence of circulating cytokines in patients with sporadic or X-linked lymphoproliferative disease with fatal infectious mononucleosis. Pediatr Hematol Oncol. 1993;10:97-99.
26. Wu C, Nguyen KB, Pien GC, et al. SAP controls T cell responses to virus and terminal differentiation of TH2 cells. Nat Immunol. 2001;2:410-414.
27. Latour S, Gish G, Helgason CD, Humphries RK, Pawson T, Veillette A. Regulation of SLAM-mediated signal transduction by SAP, the X-linked lymphoproliferative gene product. Nat Immunol. 2001;2:681-690.
28. Paya CV, Fung JJ, Nalesnik MA, et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. Transplantation. 1999;68:1517-1525.
29. Van Esser JWJ, Niesters HGM, van der Holt B, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogenic stem cell transplantation. Blood. 2002;99:4364-4369.